EX-10.6 9 d750157dex106.htm EMPLOYMENT AGREEMENT Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with...Employment Agreement • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of June 24, 2014 (the “Effective Date”), is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 324 South Hyde Park Avenue, Tampa FL 33606 (the “Company”) and Nicholas J. Virca (the “Executive”).
FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” ***CONFIDENTIAL TREATMENT REQUESTED***...Employment Agreement • September 9th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
Contract Type FiledSeptember 9th, 2014 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of September 4, 2014 (the “Effective Date”), is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 324 South Hyde Park Avenue, Tampa FL 33606 (the “Company”) and Garrison J. Hasara (the “Executive”).
CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” EMPLOYMENT AGREEMENTEmployment Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
Contract Type FiledJune 30th, 2014 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of June 24, 2014 (the “Effective Date”), is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 324 South Hyde Park Avenue, Tampa FL 33606 (the “Company”) and Nicholas J. Virca (the “Executive”).